Peripheral Arterial Disease Clinical Trial
Official title:
Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient
1. To perform an observational analysis to determine if mean translesional gradient
measurements (TLG) are associated with differences in clinical outcomes in patients with
femoropopliteal arterial disease and claudication.
2. Hypothesis: Patients stratified by a residual translesional gradient </= 11 mmHg after
peripheral revascularization or angiography alone will have better clinical outcomes
than patients with TLG > 11 mmHg as assessed by six minute walk (6MW), walking
impairment questionnaire scores (WIQ), ankle brachial index and need for repeat
procedure at 6 months.
The role of measuring translesional pressure gradients(TLG) in peripheral arterial disease
lesions below the iliac artery is unclear. In a previous study the investigators demonstrated
that a pressure wire can be effectively used to measure gradients in the femoropopliteal (FP)
arterial bed showing good correlation between TLGs recorded with exercise ankle brachial
index and walking impairment scores. However there is a no evidence that effectively
modifying the gradient or having a high residual gradient after revascularization or just
with medical therapy correlates with worse clinical outcomes.
This is a prospective, single center, observational clinical study to evaluate whether
measurement of mean residual TLG at the time of angiography and/or immediately after
endovascular revascularization are associated with clinically important outcomes in patients
with claudication symptoms.
Prior to angiography they will be asked to complete an ankle brachial index evaluation,
baseline six minute walk test and walking impairment questionnaire. Arterial access should be
obtained in the contralateral common femoral artery to the symptomatic limb if feasible.
Angiographic images are to be obtained, interpreted and clinical decisions regarding
endovascular treatment are to be made per treating physician's discretion prior to obtaining
translesional pressure gradients. In patients whose angiogram does not meet exclusion
criteria and do not have a chronic total occlusion (CTO) a baseline TLG will be obtained. A
0.014" pressure wire/catheter to measure pressure will be inserted. After baseline
calibration in the superficial femoral artery, the wire will be inserted past the narrowest
lesion into the popliteal vessel. Intra-arterial adenosine 100-200 mcg will be given for
hyperemia and measurements are to be recorded. If an intervention is planned, repeat
measurements are to be obtained at the end of the procedure. If no intervention is planned
this will be the residual or final TLG recorded. If baseline measurement are unable to
obtained due to a CTO then only a post intervention residual TLG will be obtained and
included in analysis. The operator will be blinded to the pre and post TLG measurements by
turning the display monitor away from the procedure table and towards the recorder situated
in the procedure room when measurements are being obtained.
Patients will follow up within two weeks post angiography for routine scheduled follow up and
will obtain repeat ABI, WIQ, and six minute walk if they underwent revascularization.
Treating physicians and study coordinators collecting these test measurements will be blinded
to TLG measurements but not to angiography and treatment. Patients will again be evaluated at
6 months follow up with repeat ABI, WIQ and six minute walk.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |